Latest Biotech News

Relacorilant (Lifyorli) plus nab-paclitaxel delivered a survival benefit in platinum-resistant ovarian cancer, with final overall survival results from the phase 3 ROSELLA study (NCT05257408)...

GSK moved to expand late-stage development of its gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma, outlining a plan for five Phase 3 studies. The update follows...

Researchers reported a dual-engineering strategy for allogeneic CD19 CAR T cells designed to address both antigen escape and alloimmune rejection. The approach adds an anti-rejection CD70 CAR...

A new high-throughput strategy targeting MDM2 aims to overcome radiation resistance in uveal melanoma, a malignancy where treatment durability remains a core challenge. The work outlines a...

The spring IPO market showed new momentum as Boston-based Avalyn Pharma filed an S-1 to support development of respiratory disease treatments, with multiple inhaled programs tied to pulmonary...

A Perspective piece reframed genomic sequencing’s next industry milestone around accessibility rather than only scaling throughput, usability, and integration. The report argues that sequencing...

Researchers unveiled a new early diagnostic approach for Sjögren’s syndrome using lacrimal gland color Doppler ultrasonography, aiming to detect the autoimmune disease earlier than conventional...

Two separate advances highlighted the growing use of AI in Parkinson’s diagnostics, ranging from lab-grade imaging algorithms to ultrasound-driven grading. In one report, a machine learning...

A detailed explainer laid out why preclinical-to-clinical translation remains fragile and tied current efforts to regulatory plans to reduce animal reliance. The report noted that more than 90%...

Separately from clinical science, a report described intensifying enforcement around hospital contracting practices, including a DOJ lawsuit involving OhioHealth and NewYork-Presbyterian...

Avalyn Pharma has filed its registration statement for an initial public offering, signaling a renewed push of public-market capital into respiratory fibrosis drug development. The Boston-based...

Final overall survival results from the Phase 3 ROSELLA study show relacorilant plus nab-paclitaxel reduced the risk of death versus nab-paclitaxel alone in platinum-resistant ovarian cancer. The...

GSK has outlined a late-stage development plan for a gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma after early promising data. The UK drugmaker said it intends to...

Researchers reported a dual-CAR strategy aimed at improving allogeneic CD19 CAR T cell performance by addressing two major failure modes: antigen escape and alloimmune rejection. The approach...

A new high-throughput approach targets MDM2 as a way to overcome radiation resistance in uveal melanoma. The work is designed to identify and validate combinations or mechanisms that can sensitize...

Sidewinder Therapeutics and Stipple Bio each secured large financing rounds to advance approaches for improving the targeting abilities of antibody drug conjugates (ADCs) for cancer. Both...

A new report flags that the biopharma R&D pipeline has shrunk for the first time in 30 years, raising questions about how quickly new programs are entering development across the sector. The story...

The CDC delayed the planned release of an observational study intended to show COVID vaccines reduced severe illness risk, according to reporting in the article. The piece says Acting CDC director...

Researchers developed tumor-targeted nanoparticles designed to co-deliver a macrophage engager mRNA alongside PD-L1 antibodies to boost glioblastoma immunotherapy efficacy. The work, published in...

Agilent highlighted how lab automation and instrumentation are being used to scale antibody-drug conjugate (ADC) characterization workflows. The story focuses on practical acceleration and...